US 9,809,854 B2
Biomarkers for disease activity and clinical manifestations systemic lupus erythematosus
Mary K. Crow, New York, NY (US); and Mikhail Olferiev, Mount Kisco, NY (US)
Assigned to NEW YORK SOCIETY FOR THE RUPTURED AND CRIPPLED MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY, New York, NY (US)
Filed by NEW YORK SOCIETY FOR THE RUPTURED AND CRIPPLED MAINTAINING THE HOSPITAL, New York, NY (US)
Filed on Nov. 15, 2013, as Appl. No. 13/998,598.
Claims priority of provisional application 61/726,902, filed on Nov. 15, 2012.
Prior Publication US 2014/0135225 A1, May 15, 2014
Int. Cl. C12Q 1/68 (2006.01)
CPC C12Q 1/6883 (2013.01) [C12Q 2600/158 (2013.01)] 6 Claims
 
1. A method of detecting a flare of systemic lupus erythematosus (SLE) in a subject diagnosed with SLE, consisting of:
a. assaying gene expression levels of IFIT3, MMP8, CD38, and KLRB1 in a sample of blood from the subject, wherein assaying the gene expression levels is performed using a method comprising at least one of: PCR, RNA sequencing, or microarray;
b. comparing the gene expression levels of IFIT3, MMP8, CD38, and KLRB1 in the sample from the subject with reference gene expression levels of IFIT3, MMP8, CD38, and KLRB1 in a sample of blood from a first healthy control;
c. assaying for the level of vWF in a sample of blood from the subject, wherein assaying for vWF is performed using a method comprising at least one of: ELISA, western blot, immunoblot, quantitative mass spectrometry, radioimmunoassay, immunoradiometric assay, or immunoenzymatic assay;
d. comparing the level of vWF with a reference level of vWF in a sample of blood from the first or a second healthy control; and
e. determining that the subject is having a flare of SLE when the levels of IFIT3, MMP8, CD38, and vWF from the subject are increased and the level of KLRB1 from the subject is decreased as compared to the reference levels.